|
|
|
|
A New Treatment Option For Adults With Type 2 Diabetes
THERE?S IMPORTANT NEWS FOR ADULTS WITH TYPE 2 DIABETES, THE FDA RECENTLY APPROVED A NEW MEDICINE.DANIELLE ADDAIR HAS MORE. STORY INFORMATION: THIS IS A MULTIVU SPECIAL REPORT BROUGHT TO YOU BY BRISTOL-MEYERS SQUIBB AND ASTRAZENECA. DESPITE CURRENT...
|
|
|
Pioglitazone Compared with Metformin Increases Pericardial Fat Volume in Patients with Type 2 Diabetes Mellitu
The Journal of Clinical Endocrinology & Metabolism Jan 2010 Vol.95, No. 1 456-460 J. Jonker, H. Lamb, R. van der Meer, L. Rijzewijk, L. Menting, M. Diamant, J. Bax, A. de Roos, J. Romijn and J. Smit Departments of Endocrinology and...
|
|
|
Effect of Pioglitazone on Abdominal Fat Distribution and Insulin Sensitivity in Type 2 Diabetic Patients
The Journal of Clinical Endocrinology & Metabolism 2002 Vol.87, No. 6 2784-2791 Yoshinori Miyazaki, Archana Mahankali, Masafumi Matsuda, Srikanth Mahankali, Jean Hardies, Kenneth Cusi, Lawrence J. Mandarino and Ralph A. DeFronzo University of Texas...
|
|
|
Dr Reddy's: New molecule hopes
While the results of the clinical trials on the companys new molecule, Balaglitazone, are positive, a lot needs to be done.The Dr Reddys stock surged about 4 per cent since the start of the week on announcements of encouraging Phase III trials of an anti...
|
|
|
Risk of death lower for pioglitazone and higher for sulphonylureas versus metformin, study suggests
Sulphonylureas are associated with a greater risk of heart failure and death than metformin, according to research published online in the BMJ (2009;339:b4731).Researchers from Imperial College, London, retrospectively analysed data from over 90,000 diabetic...
|
|
|
Diabetes Compound from Dr. Reddy's Found Successful in Phase III Study
India-based drug maker Dr.Reddys Laboratories and a subsidiary of Nordic Bioscience, Rheoscience, announced the success of a diabetic compound from the first phase III study. According to the study, their investigational agent, Balaglitazone, a diabetes...
|
|
|
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database
Tzoulaki I et al.The findings suggest a relatively unfavourable risk profile of sulphonylureas compared with metformin for all outcomes examined. Pioglitazone was associated with reduced all cause mortality compared with metformin. Risk of...
|
|
|
Dr. Reddy's And Rheoscience Announce Headline Results From First Phase III Clinical Trial of Balaglitazone (DRF 2593)
Reddy's Laboratories Ltd.(NYSE:RDY) and Rheoscience, a subsidiary of Nordic Bioscience A/S, today announced the headline results from the first phase III study for their investigational agent, Balaglitazone. The study (Study 307) was a phase III,...
|
|
|
Dr. Reddy's and Rheoscience Announce Headline Results from First Phase III Clinical Trial of Balaglitazone (DR
Significant reduction in HbA1c with Balaglitazone and improved safety profile HYDERABAD, India--(BUSINESS WIRE)--Jan 4, 2010 - Dr.Reddy's Laboratories Ltd. (NYSE:RDY) and Rheoscience, a subsidiary of Nordic Bioscience A/S, today announced the headline...
|
|
|
Dr. Reddy's type-2 diabetes drug balaglitazone meets primary endpoint in phase III study
Dr Reddy's Laboratories Ltd and Rheoscience, a subsidiary of Nordic Bioscience A/S, announced the headline results from the first phase-III study for their investigational agent, Balaglitazone.The study (Study 307) was a phase-III, randomized, double blind,...
|
|
|
Dr Reddy's diabetes compound meets success
Hyderabad, India-based drug maker Dr Reddys Laboratories and Rheoscience, a subsidiary of Nordic Bioscience announced the headline results from the first phase III study for their investigational agent, Balaglitazone, a diabetes compound.The study was a...
|
|
|
Headline results from first phase III study of Balaglitazone announced
Reddys Laboratories Ltd.(NYSE:RDY) and Rheoscience, a subsidiary of Nordic Bioscience A/S, today announced the headline results from the first phase III study for their investigational agent, Balaglitazone. The study (Study 307) was a phase III, randomized...
|
|
|
Dr. Reddy's and Rheoscience Announce Headline Results from First Phase III Clinical Trial of Balaglitazone (DRF 2593)
HYDERABAD, India--(BUSINESS WIRE)--Dr.Reddy?s Laboratories Ltd. (NYSE: RDY) and Rheoscience, a subsidiary of Nordic Bioscience A/S, today announced the headline results from the first phase III study for their investigational agent, Balaglitazone. The...
|
|
|
Dr. Reddy's and Rheoscience Announce Headline Results from First Phase III Clinical Trial of Balaglitazone (DR
Reddys Laboratories Ltd.(NYSE:RDY) and Rheoscience, a subsidiary of Nordic Bioscience A/S, today announced the headline results from the first phase III study for their investigational agent, Balaglitazone. The study (Study 307) was a phase III, randomized...
|
|
|
Takeda and Pfizer to Co-Promote Takeda's Actos (Pioglitazone HCl) for the Treatment of Type 2 Diabetes in Ch
- Takeda Pharmaceutical Company Limited (Takeda) and Pfizer Inc.(Pfizer) announced that they have entered into an agreement under which Pfizer in China will co-promote Takeda's Actos (pioglitazone HCl) with Tianjin Takeda Pharmaceuticals in China. The...
|
